Skip to main content
Top
Literature
1.
go back to reference Garweg JG, Zandi S (2016) Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. Graefes Arch Clin Exp Ophthalmol 254:1257–1265CrossRefPubMedPubMedCentral Garweg JG, Zandi S (2016) Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. Graefes Arch Clin Exp Ophthalmol 254:1257–1265CrossRefPubMedPubMedCentral
2.
go back to reference Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed
3.
go back to reference Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions. long-term follow-up in the Horizon trial. Ophthalmology 119:802–809CrossRefPubMed Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions. long-term follow-up in the Horizon trial. Ophthalmology 119:802–809CrossRefPubMed
4.
go back to reference Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase lll Galileo study. Br J Ophthalmol 97:278–284CrossRefPubMed Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase lll Galileo study. Br J Ophthalmol 97:278–284CrossRefPubMed
5.
go back to reference Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 Copernicus study. Am J Ophthalmol 155:429–437CrossRefPubMed Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 Copernicus study. Am J Ophthalmol 155:429–437CrossRefPubMed
6.
go back to reference Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A (2014) Lont-term outcomes in patients with retinal vein occlusion treated with ranibizumab. RETAIN Stud Ophthalmol 121:209–219 Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A (2014) Lont-term outcomes in patients with retinal vein occlusion treated with ranibizumab. RETAIN Stud Ophthalmol 121:209–219
7.
go back to reference Ogura Y, Roider J, Korobelnik JF, HOlz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, for the Galileo study group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 158:1032–1038CrossRefPubMed Ogura Y, Roider J, Korobelnik JF, HOlz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, for the Galileo study group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 158:1032–1038CrossRefPubMed
8.
go back to reference Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420CrossRefPubMed Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420CrossRefPubMed
9.
go back to reference Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year 2results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year 2results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed
10.
go back to reference Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749CrossRefPubMed Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749CrossRefPubMed
Metadata
Title
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment
Authors
Dan Călugăru
Mihai Călugăru
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 12/2016
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3458-z

Other articles of this Issue 12/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2016 Go to the issue